Recently, TYK Medicines was selected into the list of 100 Unicorn Talents in Technology, jointly released by well-known domestic industry innovation empowerment platforms such as AceBridge Capital and RSC International Innovation Hub.

100 Unicorn Talents in Technology (Specialized and Unique Edition)

In January 2021, AceBridge Capital, RSC International Innovation Hub, and more than 60 leading industrial enterprises and 100+ technological unicorns jointly released the List of 100 Unicorn Talents in Technology, lunching innovation empowerment matrices in vertical fields such as smart cities, intelligent manufacturing, automotive new four modernizations, and life sciences. China is currently at a crucial stage of transitioning from a giant manufacturer to a manufacturing power. The Specialized and Unique is the direction of transformation and upgrading in China’s manufacturing industry, as well as the winning strategy for Chinese enterprises to occupy advantages in international competition. To empower the development of specialized and unique enterprises. AceBridge Capital announced the List of 100 Unicorn Talents in Technology (Specialized and Unique Edition) in January 2023. As a pioneer enterprise in the field of innovative drug research and development, TYK Medicines was selected into the list along with companies such as Cloudwalk Technology and DeepBlue Technology empowering enterprises both upstream and downstream of the industrial chain.

At the same time, AceBridge Capital initiated the “GIA Enterprise Innovation Alliance” in conjunction with leading enterprises across various industry chains. Over 60 World-renowned and top Chinese companies including SABIC, Dow, Dassault, Covestro, Roche, FAW Benz, HYUNDAI CRADLE, Zhejiang Energy Group, Goldwind, Xpeng, FTXT, Midea, Oriental International Group, and Mengniu Dairy, among others, have joined the alliance. The aim is to lead industry trends, explore and cultivate cutting-edge technologies, facilitate breakthroughs in key technological bottlenecks, and accelerate the growth and development of specialized and cutting-edge enterprises.

The inclusion of TYK Medicines in the “100 Unicorn Talents in Technology” reflects the high recognition from the industry as well as highlights the company’s leading position in the research development of biotechnology innovative antitumor drugs. Innovation is an accelerator for the high-quality development of biotechnology, TYK Medicines has been attracting great attention and favor from capital markets; so far, the company has successfully completed five rounds of financing and received the support of nearly thirty investment institutions. In the future, TYK Medicines will continuously accelerate the research and development process of the innovative anti-tumor drug, unleash the potential of unicorns, and speed up the clinical transformation of innovative medical achievements, contributing to the development of the industry and innovation.